The Effect of Omnipod 5 Automated Insulin Delivery on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes
Authors' conclusion
Use of the OP5 system in youth and adults with CFRD led to significant improvements in multiples measures of hyperglycemia without a change in CGM-measured hypoglycemia over a 6-month period, although patient experience with hypoglycemia may limit sustained use.
Study context
- Population
- Adolescents and adults with cystic fibrosis-related diabetes initiating OP5; 65% female, median age 27.3 years, median diabetes duration 10.9 years; 23% solid organ transplant; transitioned from MDI (54%), prior Omnipod (31%) or another automated insulin delivery (AID) (15%)with sufficient data
- Participants
- 26 adolescents
- Exposure
- OP5 AID vs baseline continuous glucose monitoring (CGM) data
- Outcome
- CGM TIR (70-180 mg/dL)
Methodological detailsdual-center
- Dual-center
Main finding
As reported in the abstract
Days 1-90 vs Baseline: P < 0.001 · Days 91-180 vs Baseline: P < 0.001
Observational data: associations, not effects.
Further findings
Time above range (TAR) 181-250 mg/dL and TAR >250 mg/dL · 1-90 days and 91-180 days
- TAR 181-250 mg/dL and TAR >250 mg/dL improved at 1-90 and 91-180 days vs baseline
- P = 0.001 and P = 0.002, respectively
TBR (54-69 mg/dL, <54 mg/dL) and CV
- No significant changes in TBR or CV
Safety
Hypoglycaemia events
- Discontinued OP5 within 14 days due to persistent hypoglycemia
- 2 individuals
- Hypoglycemic seizure after 3 months of use
- 1 adult
Original publication
The Effect of Omnipod 5 Automated Insulin Delivery on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes. Diabetes Technol Ther. Published 9 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →